SavedAdd your journal

Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Myopic Maculopath

Miyopik Makülopati

Ali Hakan DURUKAN
Pages
162–167
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article describes the clinical characteristics and recent treatment strategies of CNV due to pathologic myopia

📌 3 Key Takeaways

🎯
Objective & Hypothesis:High myopia is a leading cause of visual loss, especially in younger populations, and a major cause of legal blindness in many developed countries.
📊
Key Findings & Data:Choroidal neovascularization (CNV) due to pathologic myopia is a major condition that threatens the vision of people with myopia.
💡
Conclusion & Impact:This article describes the clinical characteristics and recent treatment strategies of CNV due to pathologic myopia
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

High myopia is a leading cause of visual loss, especially in younger populations, and a major cause of legal blindness in many developed countries. Choroidal neovascularization (CNV) due to pathologic myopia is a major condition that threatens the vision of people with myopia. This article describes the clinical characteristics and recent treatment strategies of CNV due to pathologic myopia

Özet

Yüksek miyopi özellikle genç populasyonda görme kaybının önde gelen nedenidir. Birçok gelişmiş ülkede yasal körlüğün önemli nedenlerinden biridir. Patolojik miyopiye bağlı koroidal neovaskülarizasyon (KNV), miyop hastalarda görmeyi tehdit eden majör bir tablodur. Bu makalede patolojik miyopiye bağlı KNV'nin klinik özellikleri ve son tedavi stratejileri tanımlanmaktadır

🔖

Cite This Article

DURUKAN, A. H. (2015). Myopic Maculopath. Retina-Vitreus, Cilt: 23 - Sayı: 0, 162–167. https://ajindex.com/articles/308039

References (10)

  1. Ghafour I, Allan D, Foulds W. Common causes of blindness and visual han- dicap in the west of Scotland. Br J Ophthalmol 1986;67:209-13.
  2. Sperduto R, Seigel D, Roberts J, et al. Prevalence of myopia in the United States. Arch Ophthalmol 1983;101:405-7. Rufino S. Myopic Maculopathy: A review. Ophthalmologica 2012;228:197-213.
  3. Yoshida T, Ohno-Matsui K, Ohtake Y, et al.: Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002;109:712-9. Tano Y. Pathologic myopia: where are we now? American Journal of Oph- thalmology 2002;134: 645-60.
  4. Wang Q, Klein BE, Klein R, et al. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1994;35:4344-7.
  5. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of prog- ression of myopic maculopathy: a natural history study. Ophthalmology 2010;117:1595-611.
  6. Shih YF, Ho TC, Hsiao CK, Lin LL. Visual outcomes for high myopic pati- ents with or without myopic maculopathy: a 10 year follow up study. Br J Ophthalmol 2006;90:546-50.
  7. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570-3.
  8. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of pati- ents 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-7.
  9. Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascu- larization in pathologic myopia. Invest Ophthalmol Vis Sci 2010;51:3721-5.
  10. Rashid A, Grossniklaus HE. Update on the pathology of pathological myo-pia. In: Spaide RF, Ohno-Matsuyi K, Yannuzzi LA,eds. Pathologic Myopia, Springer, New York 2014;83-96. 13. Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of cho-roidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-16. 14. Verteporfin in Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with vertepor-fin. 1-year results of a randomized clinical trial-VIP report No 1. Ophthal-mology 2001;108:841-52. 15. Bandello F, Blinder K, Bressler NM, et al. Verteporfin in photodynamic therapy: report No 5. Ophthalmology 2004;111:2144. 16. Hayashi K, Ohno-Matsui K, Teramukai S, et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese